Johannes Zakrzewski, M.D., is an Associate Member of the Center for Discovery and Innovation and a Pediatric Stem Cell Transplant Attending Physician at Hackensack University Medical Center. He is board-certified in Pediatrics and Pediatric Hematology/Oncology.
The Zakrzewski laboratory focuses on the development of innovative therapies for the treatment of myeloma, lymphoma and other cancers, as well as T cell deficiency. Specifically, we are investigating novel strategies for cancer immunotherapy and immunosurveillance by exploiting the endogenous capacity of the thymus to generate genetically modified T cells, and by harnessing advances in gene therapy and chimeric antigen receptor technology. We are also utilizing immunobioengineering methodologies to achieve thymus-independent T cell generation. Finally, in collaboration with ImmuneTarget Inc. we are pursuing a drug development program aimed at improving the understanding of NF-κB and oxidative stress as therapeutic targets in multiple myeloma and other cancers. We recently entered the late preclinical stage of development of a novel small molecule inhibitor drug.